Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound Docetaxel vs Taxotere in Advanced Gastric Cancer
NCT05705635Phase 2Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jan 2023
- Primary completion
- May 2023
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of albumin-bound docetaxel in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by CSPC ZhongQi Pharmaceutical Technology. Status: unknown.
02
Drugs
albumin-bound docetaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05705635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05705635.